J&J posts lower-than-expected earnings

Though Johnson & Johnson (NYSE: JNJ) posted growth in its second quarter earnings, the profits were less-than-expected, giving mixed signals to the medical device industry's overall health. But as experts and analysts crunch the numbers, J&J CFO Dominic Caruso isn't worried.

"It's good to look at these businesses over longer periods and not just an individual quarter," Caruso said on a conference call. Sutures, for example, are showing stable growth, and while they are not back at their peak levels, they are a sign of the overall economy's health. Overall sales in devices grew 4.1 percent to $6.13 billion, markedly lower than analysts' expections of 7 percent growth.

Orthopedics in particular have felt the pressure from hospitals that are trying to cut costs. Stocks of rivals in this segment traded down after J&J's announcement.

- read the article

ALSO: Stryker Corp on Tuesday reported second-quarter earnings that met analysts' expectations as strong demand for medical and surgical equipment offset sluggish sales of hip and knee devices. News

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.